Back to results
US 8,133,879 B2Granted
Myocardial perfusion imaging methods and compositions
AssigneeGilead Sciences, Inc.
InventorsLuiz Belardinelli, Mitchell Rosner
Life of this patent
Estimating the term…
Abstract
The present disclosure provides 2-adenosine N-pyrazole compounds of structural formula shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds in a variety of applications including myocardial perfusion imaging methods.
Claims13
A pharmaceutical composition comprising
- a) CVT-3146, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl)pyrazol-4-yl)-N-methylcarboxamide, which has the formula:
- b) at least one liquid carrier selected from the group consisting of water, distilled water, de-ionized water, saline, a buffer, and combinations thereof,
- c) at least one sodium phosphate buffer;
- d) EDTA;
- and
- e) propylene glycol in an amount from about 5% to about 25% (w:v), and wherein the pH of said pharmaceutical composition is from about 6 to about 8.
3 more elements
A pharmaceutical composition comprising:
- a) CVT-3146, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl)pyrazol-4-yl)-N-methylcarboxamide, which has the formula:
- b) water;
- c) at least one sodium phosphate buffer;
- d) 0.1% EDTA;
- e) propylene glycol in an amount of 15% (w:v), and wherein the pH of said pharmaceutical composition is about 7.
2 more elements
A pharmaceutical composition for intravenous administration comprising
- a) CVT-3146, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl)pyrazol-4-yl)-N-methylcarboxamide, which has the formula:
- b) at least one liquid carrier selected from the group consisting of water, distilled water, de-ionized water, saline, a buffer, and combinations thereof,
- c) at least one sodium phosphate buffer;
- d) EDTA;
- and
- e) propylene glycol in an amount from about 5% to about 25% (w:v), wherein the pH of said pharmaceutical composition is from about 6 to about 8, and further wherein the composition may be administered intravenously as a single bolus injection.
3 more elements
Dependencies are inferred from the claim text.